Revista medica del Instituto Mexicano del Seguro Social · 2026
[Efficacy of octreotide LAR and lanreotide autogel in acromegaly assessed by SAGIT].
СтатьяНаблюдательное исследованиеСравнительное исследованиеАннотация на английскомНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Núñez-Martínez Francisco Javier, Chávez-Lárraga Alejandro de Jesús, Hernández-Salazar Enrique, Martínez-Sánchez Brian Humberto, Velasco-Santos Jorge Isaac
Аннотация
BACKGROUND: Biochemical control has been the main objective in the treatment of acromegaly; however, GH and IGF-1 levels do not necessarily translate into clinical response, as they fail to account for the complexity of symptoms and patients' perceptions. The SAGIT instrument was developed to assist in assessing the status and evolution of the disease in patients with acromegaly and facilitate decision-making.
OBJECTIVE: To compare the efficacy of octreotide LAR and lanreotide autogel in managing patients with acromegaly using the SAGIT instrument.
MATERIAL AND METHODS: Observational, unicentric study, conducted in 2022 at a referral hospital in León, Guanajuato, Mexico.
RESULTS: Of 37 patients evaluated, 26 were included. 13 (50%) received lanreotide autogel and 11 (42.3%) received octreotide LAR. Disease control, as measured by IGF-1 levels, was achieved in 10 patients (42.3%). When assessing control using the SAGIT instrument, 8 patients (30.7%) met control criteria. Octreotide LAR showed greater disease control as assessed by SAGIT compared to lanreotide autogel (p = 0.043).
CONCLUSIONS: Based on the SAGIT instrument, octreotide LAR is more effective for disease control in patients with acromegaly than in those patients treated with lanreotide. The preferential use of octreotide LAR could be recommended in resource-limited settings.
OBJECTIVE: To compare the efficacy of octreotide LAR and lanreotide autogel in managing patients with acromegaly using the SAGIT instrument.
MATERIAL AND METHODS: Observational, unicentric study, conducted in 2022 at a referral hospital in León, Guanajuato, Mexico.
RESULTS: Of 37 patients evaluated, 26 were included. 13 (50%) received lanreotide autogel and 11 (42.3%) received octreotide LAR. Disease control, as measured by IGF-1 levels, was achieved in 10 patients (42.3%). When assessing control using the SAGIT instrument, 8 patients (30.7%) met control criteria. Octreotide LAR showed greater disease control as assessed by SAGIT compared to lanreotide autogel (p = 0.043).
CONCLUSIONS: Based on the SAGIT instrument, octreotide LAR is more effective for disease control in patients with acromegaly than in those patients treated with lanreotide. The preferential use of octreotide LAR could be recommended in resource-limited settings.